B of A Securities Maintains Underperform on PTC Therapeutics, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains an Underperform rating on PTC Therapeutics (NASDAQ:PTCT) but raises the price target from $25 to $32.
June 21, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities has maintained an Underperform rating on PTC Therapeutics but raised the price target from $25 to $32.
The Underperform rating suggests a negative outlook, but the raised price target indicates some positive expectations. The mixed signals likely result in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100